FB23

Catalog No.S6291 Batch:S629102

Print

Technical Data

Formula

C18H14Cl2N2O3
Molecular Weight 377.22 CAS No. 2243736-35-6
Solubility (25°C)* In vitro DMSO 75 mg/mL (198.82 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description FB23 is a potent and selective inhibitor of FTO demethylase with IC50 of 60 nM. FB23 directly binds to FTO and selectively inhibits FTO's mRNA N6-methyladenosine (m6A) demethylase activity.
Targets
FTO demethylase [1]
(Cell-free assay)
60 nM
In vitro

FB23 treatment inhibits acute myeloid leukemia (AML) cells proliferation with IC50 values of 44.8 μM, 23.6 μM for NB4 and MONOMAC6 AML cells. FB23 treatment causes the significant suppression of MYC targets, E2F targets, and G2M checkpoint signal cascades, which may contribute to the inhibitory effects of FTO inhibitors and FTO KD on cell cycle and proliferation. FB23 treatments activates apoptosis and p53 pathways.[1]
In vivo

Pharmacological inhibition of FTO by FB23-2 substantially suppresses leukemia progression and prolongs survival.[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    AML cell lines

  • Concentrations

    1-50 μM

  • Incubation Time

    24 h, 48 h, 72 h, 96 h

  • Method

    AML cells are seeded and treated with DMSO or FB23 for 24 h, 48 h, 72 h, or 96 h. The cell proliferations are determined with CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay. AML cells are treated with DMSO or 5 μM FB23-2 for 72 hr for dot blot assay.

Selleck's FB23 has been cited by 1 publication

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner [ Oncogene, 2022, 41(20):2860-2872] PubMed: 35422475

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.